Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials

Autor: Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig Sanz, Lluís., Bachelez, Hervé, Chouela, E., Imafuku, S., Thaçi, Diamant, Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R., Universitat Autònoma de Barcelona
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
Adolescent
Administration
Oral
Dermatology
Placebo
Risk Assessment
Severity of Illness Index
030207 dermatology & venereal diseases
03 medical and health sciences
Young Adult
All institutes and research themes of the Radboud University Medical Center
0302 clinical medicine
Piperidines
Psoriasis Area and Severity Index
Internal medicine
Psoriasis
Severity of illness
medicine
Janus Kinase Inhibitors
Humans
Pyrroles
Protein Kinase Inhibitors
Janus kinase inhibitor
Aged
Randomized Controlled Trials as Topic
Aged
80 and over
Tofacitinib
Dose-Response Relationship
Drug
business.industry
Original Articles
Dermatology Life Quality Index
Middle Aged
medicine.disease
Clinical Trial
Clinical trial
Pyrimidines
Chronic Disease
Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5]
Quality of Life
Female
business
Zdroj: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
British Journal of Dermatology, 180, 1, pp. 67-75
The British Journal of Dermatology
British Journal of Dermatology, 180, 67-75
ISSN: 0007-0963
Popis: Summary Background Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate‐to‐severe chronic plaque psoriasis. Objectives To consider the benefits and risks of tofacitinib in patients with moderate‐to‐severe psoriasis. Methods Data were pooled from one phase II, four phase III and one long‐term extension study comprising 5204 patient‐years of tofacitinib treatment. Efficacy end points included patients achieving Physician's Global Assessments of ‘clear’ or ‘almost clear’, ≥ 75% and ≥ 90% reduction in Psoriasis Area and Severity Index (coprimary end points) and improvements in Dermatology Life Quality Index score, Hospital Anxiety and Depression Scale depression score and Itch Severity Item score, at weeks 16 and 52. Safety data were summarized for 3 years of tofacitinib exposure. Results Tofacitinib 5 and 10 mg twice daily (BID) showed superiority over placebo for all efficacy end points at week 16, with response maintained for 52 weeks of continued treatment. Tofacitinib improved patients’ quality of life and was well tolerated. Rates of safety events of interest (except herpes zoster) were similar to those in the published literature and healthcare databases for other systemic psoriasis therapies. Tofacitinib 10 mg BID demonstrated greater efficacy than 5 mg BID. Conclusions Tofacitinib has a benefit–risk profile in moderate‐to‐severe psoriasis consistent with that of other systemic treatments.
What's already known about this topic? Psoriasis is a chronic, systemic inflammatory disease, which has a significant impact on patients’ health‐related quality of life.Although several existing psoriasis treatments are efficacious and well tolerated in many patients, some patients require treatment switching, and a proportion of patients remain untreated or undertreated.Potential challenges to the use of existing therapies include safety issues and limited efficacy in some patients with conventional oral psoriasis treatments, inconvenience of topical treatments and the requirement for parenteral administration of biologics. What does this study add? Consistent efficacy and a safety profile consistent with that seen in rheumatoid arthritis, psoriatic arthritis and ulcerative colitis were demonstrated for oral tofacitinib in patients with moderate‐to‐severe psoriasis.Tofacitinib has a benefit–risk profile in patients with moderate‐to‐severe psoriasis that is consistent with that of other systemic psoriasis treatments. Linked Comment: Fleming. Br J Dermatol 2019; 180:13–14. Plain language summary available online Respond to this article
Databáze: OpenAIRE
Externí odkaz: